ArticleJournal of mid-life health
Clinical Effect of
Article in Journal of mid-life health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The deficiency of estrogen becomes clinically more overt over time and correlated with amounts of genitourinary syndromes of menopause (GSM). Our study aimed at examining the clinical effect of Subjects and Methods: This study included 31 patients with GSM symptoms. The treatment administered to patients included in this study was the daily use of vaginal treatment of HERCET®-w gel. Before, 3 months, and 6 months after HERCET®-w gel treatment, each patient's baseline characteristic data were collected. Results: Our data showed that HERCET®-w gel could significantly improve some index or questionnaire in urinary symptoms including the Urogenital Distress Inventory 6, the Vaginal Health Index, or pH value. It also showed a significant increase in sexual function after 6 months treatment of HERCET®-w. Conclusion: HERCET®-w on the women with GSM after 6 months could significantly improve GSM. It also showed an obvious progress of patients' sexual function in the Female Sexual Function Index score in the 6-month follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.